The Migraine Market
The migraine market is a large underserved patient population. More than 31 million Americans - or 12 percent of the US adult population or 1 in 4 households - suffer from migraine, a serious and debilitating neurologic disease.
Large Opportunity for Migraine Patch
The Burden of Migraine-Related Nausea
"For people suffering from migraine, nausea is the most important clinical symptom other than head pain."
Dr. Richard Lipton
Vice Chairman and Professor
Department of Neurology
Albert Einstein College of Medicine
Why Sumatriptan?
Triptan drugs are the preferred class of treatment for migraine, accounting for 94 percent of the 13 million prescriptions, of migraine prescriptions and 97 percent of migraine sales.
Total US Migraine Prescriptions: 13 Million*
*Data: MAT June 2011. Triptans include Treximet. Analgesic Combos = analgesic combos + Cambia.Patient Dissatisfaction
Approximately 11 million patients progress to a second triptan option for migraine treatment, and approximately 6.5 million progress to a third. Reasons for triptan progression include:
- Inconsistent relief: affecting approximately six million patients
- Adverse events related to treatment including those known as triptan sensations affecting approximately 11 million patients)
Lipton, Buse Data presented at the 53rd Annual Scientific Meeting of the American Headache Society (AHS), June 2011. Analysis funded through an unrestricted grant provided by NuPathe Inc.Why a Patch for Migraine?